STOCK TITAN

Alpha Cognition Announces Appointment of VP Finance and Accounting

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company focused on developing therapies for neurodegenerative disorders, has appointed Henry Du as VP of Finance and Accounting and interim Chief Financial Officer (CFO). Du brings over 20 years of experience in corporate accounting and finance, with a strong background in the life science industry.

Prior to joining Alpha Cognition, Du held senior positions at Amplify Surgical and HUYABIO International, where he played key roles in achieving financial goals and establishing accounting policies. He also served in leadership roles at Eledon Pharmaceuticals, United Auto Credit, and Avanir Pharmaceuticals.

CEO Michael McFadden stated that Du's appointment is important as the company prepares for commercialization. Du expressed excitement about joining Alpha Cognition at this critical juncture, emphasizing the opportunity to contribute to a company on the verge of a major product launch.

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), un'azienda biofarmaceutica focalizzata nello sviluppo di terapie per i disturbi neurodegenerativi, ha nominato Henry Du come VP di Finanza e Contabilità e CFO ad interim. Du porta con sé oltre 20 anni di esperienza nella contabilità e finanza aziendale, con un solido background nell'industria delle scienze della vita.

Prima di unirsi ad Alpha Cognition, Du ha ricoperto ruoli di alto livello presso Amplify Surgical e HUYABIO International, dove ha avuto un ruolo chiave nel raggiungere obiettivi finanziari e nell'istituzione di politiche contabili. Ha anche ricoperto posizioni di leadership presso Eledon Pharmaceuticals, United Auto Credit e Avanir Pharmaceuticals.

Il CEO Michael McFadden ha dichiarato che la nomina di Du è importante mentre l'azienda si prepara alla commercializzazione. Du ha espresso entusiasmo per l'arrivo in Alpha Cognition in questo momento cruciale, sottolineando l'opportunità di contribuire a un'azienda in procinto di lanciare un'importante prodotto.

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), una empresa biofarmacéutica centrada en el desarrollo de terapias para trastornos neurodegenerativos, ha nombrado a Henry Du como VP de Finanzas y Contabilidad y CFO interino. Du aporta más de 20 años de experiencia en contabilidad corporativa y finanzas, con un fuerte historial en la industria de las ciencias de la vida.

Antes de unirse a Alpha Cognition, Du ocupó puestos senior en Amplify Surgical y HUYABIO International, donde desempeñó roles clave en el logro de objetivos financieros y en el establecimiento de políticas contables. También ocupó posiciones de liderazgo en Eledon Pharmaceuticals, United Auto Credit y Avanir Pharmaceuticals.

El CEO Michael McFadden declaró que el nombramiento de Du es importante mientras la empresa se prepara para la comercialización. Du expresó su entusiasmo por unirse a Alpha Cognition en este momento crítico, enfatizando la oportunidad de contribuir a una empresa a punto de lanzar un importante producto.

알파 코그니션 주식회사 (CSE: ACOG) (OTCQB: ACOGF)는 신경퇴행성 질환 치료제 개발에 중점을 둔 생명과학 제약 회사로, 헨리 두를 재무 및 회계 부사장 및 임시 최고 재무 책임자(CFO)로 임명했습니다. 두는 생명과학 산업에서의 강력한 배경으로 기업 회계와 재무에서 20년 이상의 경험을 가지고 있습니다.

알파 코그니션에 합류하기 전에, 두는 앰플리파이 서지컬휴야바이오 인터내셔널에서 고위직을 맡아 재무 목표 달성과 회계 정책 수립에 중요한 역할을 했습니다. 또한 엘레돈 제약, 유나이티드 오토 크레딧 및 아바니르 제약에서도 리더십 역할을 수행했습니다.

CEO 마이클 맥패든은 두의 임명이 회사가 상업화를 준비하는 데 중요하다고 언급했습니다. 두는 이 중요한 시점에 알파 코그니션에 합류할 수 있게 되어 기쁘다고 말하며, 주요 제품 출시를 앞둔 회사에 기여할 기회를 강조했습니다.

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), une entreprise biopharmaceutique axée sur le développement de thérapies pour les troubles neurodégénératifs, a nommé Henry Du en tant que VP des Finances et de la Comptabilité et Directeur Financier (CFO) par intérim. Du apporte plus de 20 ans d'expérience en comptabilité et en finances d'entreprise, avec un solide parcours dans l'industrie des sciences de la vie.

Avant de rejoindre Alpha Cognition, Du a occupé des postes de haut niveau chez Amplify Surgical et HUYABIO International, où il a joué un rôle clé dans l'atteinte des objectifs financiers et l'établissement de politiques comptables. Il a également exercé des fonctions de leadership chez Eledon Pharmaceuticals, United Auto Credit et Avanir Pharmaceuticals.

Le PDG Michael McFadden a déclaré que la nomination de Du est importante alors que l'entreprise se prépare à la commercialisation. Du a exprimé son enthousiasme à rejoindre Alpha Cognition à ce moment critique, soulignant l'opportunité de contribuer à une entreprise sur le point de lancer un produit majeur.

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Therapien für neurodegenerative Erkrankungen konzentriert, hat Henry Du zum VP für Finanzen und Rechnungswesen sowie interimistischen Finanzvorstand (CFO) ernannt. Du bringt über 20 Jahre Erfahrung in der Unternehmensbuchhaltung und -finanzierung mit, mit einem starken Hintergrund in der Biowissenschaftsindustrie.

Vor seinem Eintritt bei Alpha Cognition hatte Du leitende Positionen bei Amplify Surgical und HUYABIO International inne, wo er eine Schlüsselrolle bei der Erreichung finanzieller Ziele und der Etablierung von Rechnungslegungsrichtlinien spielte. Er hatte auch Führungspositionen bei Eledon Pharmaceuticals, United Auto Credit und Avanir Pharmaceuticals.

CEO Michael McFadden erklärte, dass Dus Ernennung wichtig sei, da das Unternehmen sich auf die Kommerzialisierung vorbereitet. Du äußerte seine Freude über den Beitritt zu Alpha Cognition zu diesem kritischen Zeitpunkt und betonte die Gelegenheit, zu einem Unternehmen beizutragen, das kurz vor der Markteinführung eines wichtigen Produkts steht.

Positive
  • Appointment of experienced VP of Finance and Accounting with over 20 years in the life science industry
  • New hire brings expertise in achieving positive EBITDA and profitability
  • Strategic addition to the team as the company prepares for commercialization
Negative
  • None.

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, announces that Henry Du has joined Alpha Cognition as the VP of Finance and Accounting and interim Chief Financial Officer (CFO).

(Photo: Business Wire)

(Photo: Business Wire)

“Henry brings to the Company over 20 years of experience in corporate accounting and finance, with a strong business background in the life science industry and we believe this an important addition to the Company as we prepare for commercialization,” said Michael McFadden, CEO of the Company.

Prior to joining Alpha Cognition, Mr. Du was Sr. Vice President of Accounting and Administration at Amplify Surgical, a medical device company focused on developing innovative endoscopic surgical techniques and spinal implant technologies, where he led the finance and accounting functions, as well as administrative roles including HR, payroll, compliance, corporate legal, and investor relations. During his tenure there, he was instrumental in helping the company achieve consistent positive EBITDA and profitability, along with doubling average daily operating liquidity. Mr. Du was also VP of Finance and Senior Corporate Controller at HUYABIO International, a leader in globalizing Chinese pharmaceutical innovation, where he established the commercial accounting policy for the company’s product launch in Japan. Prior to HUYABIO, Mr. Du served in leadership roles at Eledon Pharmaceuticals (formerly Novus Therapeutics), a publicly traded clinical-stage biopharmaceutical company, United Auto Credit, and at Avanir Pharmaceuticals.

“I am excited to join Alpha Cognition at such a critical juncture,” said Henry Du. “The opportunity to contribute to a company that is not only on the cusp of a major product launch but is also dedicated to delivering life-changing treatments is incredibly compelling. I look forward to helping steer the financial strategy for continued success.”

About Alpha Cognition Inc.

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.

ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.

This news release includes forward-looking statements within the meaning of applicable United States and Canadian securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “expect”, “believe”, and “continue”, or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the Company’s clinical development activities, and the timing and results of clinical trials. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital, including bridge funding, to implement our plans to commercialize ZUNVEYL , risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL , risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at www.sedarplus.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Form S-1 registration statement as filed with the SEC on June 14, 2024 and available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.

For further information:

Michael McFadden, CEO

Tel: 1-858-344-4375

info@alphacognition.com

Source: Alpha Cognition Inc.

FAQ

Who is the new VP of Finance and Accounting at Alpha Cognition (ACOGF)?

Henry Du has been appointed as the new VP of Finance and Accounting and interim Chief Financial Officer (CFO) at Alpha Cognition (ACOGF).

What is Henry Du's background before joining Alpha Cognition (ACOGF)?

Henry Du has over 20 years of experience in corporate accounting and finance, with a strong background in the life science industry. He previously held senior positions at Amplify Surgical and HUYABIO International, and served in leadership roles at Eledon Pharmaceuticals, United Auto Credit, and Avanir Pharmaceuticals.

Why did Alpha Cognition (ACOGF) appoint a new VP of Finance and Accounting?

Alpha Cognition (ACOGF) appointed Henry Du as VP of Finance and Accounting to strengthen their team as they prepare for commercialization. CEO Michael McFadden stated that this is an important addition to the company at this critical juncture.

What are Alpha Cognition's (ACOGF) main business activities?

Alpha Cognition (ACOGF) is a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders. They are currently preparing for a major product launch.

ALPHA COGNITION INC NEW

OTC:ACOGF

ACOGF Rankings

ACOGF Latest News

ACOGF Stock Data

35.50M
149.58M
Biotechnology
Healthcare
Link
United States of America
Vancouver